# A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

> **NCT03525574** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 507 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT03525574
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2023-01-09
- **Final completion:** 2023-01-09
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525574, "A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03525574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*